Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vir Biotechnology (VIR – Research Report) and Moderna (MRNA ...

A source tells Bloomberg that Stephane Bancel will step down as the company’s Chief Commercial Officer, but retain the role of ...

Gift Article. 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Northwestern University filed a patent infringement ...

Moderna is facing allegations that it misused innovations from researchers at Northwestern University to develop its mRNA COVID-19 vaccines, which became widely available to the public in 2021 to ...

GSK says it owns seven patents that “provide the foundation” for Moderna’s messenger RNA vaccine portfolio, and is now suing the biotechnology company for infringement. At issue is the work of a team ...

The lawsuits claim that Moderna used and profited from crucial mRNA technology in its COVID-19 vaccine Spikevax and respiratory syncytial virus shot mResvia. The lawsuits, filed separately in the U.S.

Moderna Inc.’s shots for Covid-19 and respiratory syncytial virus infringe as many as seven GSK Plc patents related to mRNA vaccine-delivery technology, the company said in a pair of federal lawsuits.

The Moderna lawsuits echo similar claims made by GSK when it sued Pfizer and BioNTech for allegedly infringing upon the company’s mRNA patents back in April. At the time, Pfizer voiced ...

By Blake Brittain (Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology ...

The stock’s market value topped $1 billion in 2021 but saw its value slashed in half just a year later as Moderna Inc. along with the Pfizer Inc. and BioNTech SE partnership dominated the market ...

The new COVID-19 vaccine rolled out across the country last month, giving people access to the most recent versions of the Moderna, Pfizer, and Novavax shots. But, given that you have options ...